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Summary Reproductive outcomes and health of offspring were investigated in 340 patients with Hodgkin's
disease first treated at Mount Vernon Hospital, Middlesex, England, at ages under 40 (females) or 45 (males)
during 1970-91. Information on offspring was obtained from case-notes and postal questionnaires to the
patients. Eleven men and 16 women who had conceived any children after treatment were then interviewed.
There was no excess of stillbirths, low birthweight or congenital malformations, and no cancers have occurred
in the 49 offspring after treatment. There was a significant excess of twins, compared with national
expectations, in offspring of female patients (RR=8.52, P=0.025). Aggregation of series from the literature
also showed an excess of twins. Chromosomes from cultures of peripheral lymphocytes from 45 children born
to 25 patients (11 men and 14 women) after treatment were examined for numerical abnormalities and for
structural abnormalities at the 550 or greater band level of resolution. All were normal except in one child with
Down's syndrome (47, XY,+21), for whom we found the origin of the trisomy was from the parent without
Hodgkin's disease. The chromosome constitution was also abnormal in one miscarriage (69, XXY; originating
from the parent without Hodgkin's disease) and one termination (45, X; for which the parental origin could
not be determined) after treatment. The study adds to previous questionnaire data and for the first time
provides data also from chromosome analysis, that offspring of patients treated in adulthood for Hodgkin's
disease are not at greatly raised risk of genotoxic or other adverse outcomes as a consequence of their parent's
treatment. The numbers of offspring assessed in the literature remains small, however, and surveillance of
larger numbers of subjects is needed to enable reliable treatment-specific analyses.
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Radiotherapy and alkylating chemotherapy are known to
cause cancer, but whether they can also cause germ cell
mutations and hence affect subsequent generations, is
uncertain (Draper, 1989). The offspring of patients with
cancer treated by radiotherapy and chemotherapy are
important to study in this context since their exposures are
large and well-documented. Their risks are also of clinical
importance, for counselling of young cancer patients whose
fertility is often retained after treatment, and who are
uncertain whether to have children. Published studies of the
offspring of cancer survivors mainly concern childhood
cancer survivors (Mulvihill et al., 1987b; Li et al., 1987;
Hawkins et al., 1989; Hawkins, 1991; Green et al., 1991),
many of whom were not treated with potentially mutagenic
therapy and whose treatment was many years before
conception. Studies of offspring of adult cancer patients
have been relatively small, totalling a few hundred children
born after treatment. In one study of childhood cancer
survivors, chromosomes were examined in 24 offspring (Li et
al., 1979), but no such examinations appear to have been
published for offspring of adult cancer patients.
Materials and methods
We studied children of patients treated for Hodgkin's disease
at Mount Vernon Hospital, near London, which has been a
member of the British National Lymphoma Investigation
(BNLI) since 1970. To focus on patients who had an
appreciable possibility of having children after treatment,
we extracted from the BNLI files, data on all patients with
Hodgkin's disease first attending Mount Vernon Hospital
during 1970-1991, who had survived to age 18 years and
were aged under 40 years (females) or 45 years (males) at
incidence of the tumour. The BNLI files and the case-notes of
the patients were searched for records of children. Also, we
mailed a questionnaire to the patients, and a reminder if
necessary, asking about fertility, pregnancies and their
outcomes, and the health of the children. When any children
conceived after treatment were identified, we requested an
interview with the patient, unless psychological problems or
illness made this inappropriate. At interview we asked about
obstetric history and abnormalities in the children, and
whether the patient would agree to blood samples being
taken from their children for cytogenetic examination.
Counselling was given on the reason for the cytogenetic
tests and the consequences of the potential findings, and the
patients were told that they could be informed of the results,
or not, as they wished. Arrangements were made for
specialist genetic counselling, if needed. For patients who
agreed, blood samples were taken from all children, whether
born before or after treatment. Cultures of peripheral
lymphocytes were examined after semi-synchronisation with
fluorodeoxyuridine (Webber and Carson, 1983) to detect
numerical or structural chromosome abnormality at the 550
or greater band level of resolution. Four G-banded cells were
analysed and a total of 10 cells counted in each case. The
examination was conducted blind as to whether the child had
been born before or after treatment, and the type of
treatment. If an abnormality was found, samples were
requested from both parents to determine whether the
abnormality was a de-novo mutant, and if so, the parental
origin of the abnormality, by following the segregation of
PCR probes that defined appropriate polymorphisms (Sher-
man et al., 1994).
To analyse how birth characteristics of the offspring of the
Hodgkin's disease patients compared with the birth char-
acteristics of children in the general population, we calculated
relative risks for the Hodgkin's disease offspring (Breslow
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and Day, 1987), using as the comparison national births data
for as many years as available (see Table II) of the period
when the Hodgkin's patients' offspring had been born.
Trends in percentages were analysed by the method of
Cuzick (1985); exact confidence intervals for percentages were
based on the binomial distribution.
Results
A total of 340 patients with Hodgkin's disease incident at the
study ages and who had survived to at least age 18 years,
were treated at Mount Vernon Hospital during 1970-1991.
All but 15 (4%) were aged 15 years or more at incidence of
the disease, and most [202 (59%)] were male. We examined
BNLI records for all of the patients, and case-notes of all
patients except ten (seven men, three women) whose case
notes could not be traced, and 53 whose notes were not
examined because they had died, and either it was known
that they had been too ill to conceive or deliver, or it was
known by the consultant treating them that they had not in
fact had children. At the time of the study 71 of the patients
had died, and 27 others were not mailed because no current
address could be traced (15), emigration (2), the patient
declined to take part during preliminary interviews (3),
psychiatric illness (2), or at the consultant's request (5).
Questionnaires were sent to the remaining 242 patients (100
women, 142 men), and after reminders replies were received
from 143 (59%; similar rates in men and women).
From the case-notes plus questionnaires we found 18 men
and 26 women who had had any children born after first
treatment for Hodgkin's disease. There were no women for
whom children reported in the questionnaire were not already
known from the case-notes, except that one patient was
among the three women whose notes could not be located.
There were six men, however, for whom children were first
ascertained from the questionnaire. Eight of the patients with
children born after treatment had also had children before
treatment; 36 had not. None had conceived children during
treatment. The age range at treatment of the men with
children conceived after treatment was 10-35 years and for
the corresponding women was 14 to 31 years.
Table I compares characteristics of patients who had and
those who did not conceive any children after treatment. The
proportion of patients with children reported after treatment
was lower for men (17.8%) than women (34.7%), for men
who had had only chemotherapy than for men in other
treatment groups (P heterogeneity <0.05), and for the most
recently treated patients (who have as yet had a short time in
which such conceptions could have occurred), and men
treated before 1975, than for those first treated at other times.
For women, stage of Hodgkin's disease was unrelated to the
proportion who bore children, but in men the proportion
fathering children was lower for those with higher stage
disease (P trend < 0.05). In women, the proportion
conceiving was greatest for those treated before age 25 (P
trend=0.01); in men it was greatest for those treated in their
20s. These results were similar, although less stable based on
smaller numbers, when we included patients childless after
treatment only if in response to the questionnaire they stated
that this was because of infertility due to the disease or its
treatment, rather than, for instance, because they did not
want children, or their partner was infertile.
We were able to interview 11 of the 18 men and 16 of the
26 women known to have conceived any children after
treatment and in all but one instance we gained agreement to
take blood specimens from their children. The reasons for
non-interview of the remainder were in five that multiple
mailings produced no response; for five we did not request
interview because the patient was ill or undergoing divorce;
two patients declined to be interviewed; two agreed but
interview proved impractical; one could not be traced; and
two men replied to the questionnaire over a year late, when
data collection for the study was completed. For nine of these
patients a postal questionnaire had been completed; these
questionnaires reported no congenital malformations or
cancers in the offspring.
The 27 patients had a total of six liveborn children (three
male, three female) before first treatment and 49 liveborn
children (24 male, 25 female) after that date. Sixteen of the
children were conceived after chemotherapy to the parent, 25
after radiotherapy and eight after combined modality
therapy. None of these children were the product of sperm
stored before treatment of a male patient, except possibly in
Table I Parenthood after treatment of Hodgkin's disease, in patients who survived at least 1 year
Any children after treatment No children after treatment Percentage with any children
(a) (b) after treatment (a/a + b)
Males Females Males Females Males Females
n % n % n % n % % %
Year of first treatment
< 1975 2 11.1 7 26.9 15 18.1 7 14.3 11.8 50.0
1975-79 6 33.3 7 26.9 23 27.7 6 12.2 20.7 53.8
1980-84 6 33.3 9 34.6 14 16.9 11 22.4 30.0 45.0
) 1985 4 22.2 3 11.5 31 37.3 25 51.0 11.4 10.7
Type of treatment
Chemotherapy 3 16.7 10 38.5 41 49.4 21 42.9 6.8 32.3
Chemo + radio 3 16.7 1 3.8 7 8.4 4 8.2 30.0 20.0
Radiotherapy 12 66.7 15 57.7 35 42.2 24 49.0 25.5 38.5
Stage
I 9 50.0 5 19.2 19 22.9 7 14.3 32.1 41.7
II 4 22.2 13 50.0 27 32.5 27 55.1 29.0 32.5
III 4 22.2 6 23.0 22 26.5 10 20.4 15.4 37.5
IV 1 5.6 2 7.7 15 18.1 5 10.2 6.3 28.6
Age at first treatment
(years)
<20 2 11.1 9 34.6 14 16.9 10 20.4 12.5 47.4
20-24 8 44.4 12 46.2 19 22.9 12 24.5 29.6 50.0
25-29 4 22.2 3 11.5 15 18.1 11 22.4 21.1 21.4
30-34 3 16.7 2 7.7 19 22.9 8 16.3 13.6 20.0
35-39 1 5.6 0 0 7 8.4 8 16.3 12.5 0
40-44 0 0 0 0 9 10.8 0 0 0 -
Total (all patients) 18 100 26 100 83 100 49 100 17.8 34.7Offspring of Hodgkin's disease patients
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Table II Characteristics at birth ofchildren born after parental treatment for Hodgkin's disease compared with all
births in England and Wales
Children ofHodgkin's
disease patients
(n = 49; 1973-92) National births
No. with No. with RR (95% CI)
characteristic % characteristic % Hodgkin's off-
spring
Stillbirths 0 - 89 635 0.7
Sex of livebirth
Female 25 51.0 6 309 167 48.7 1.0
Male 24 49.0 6 655 961 51.3 0.91 (0.52-1.59)
Singleton/multiple pregnancy
Singleton 45 95.7 11 412 143 98.9 1.00
Twin and higher order 2 4.3 121 821 1.1 4.16 (1.01-17.16)
Birthweight liveborn (g)b,C
<2500 5 10.6 528 989 6.7 1.58 (0.52-4.26)
2500-2999 6 12.8 1 436 901 18.3 0.70 (0.28-1.76)
3000-3499 18 38.3 3 014 495 38.3 1.00
3500-3999 15 31.9 2 203 032d 28.0 1.14 (0.57-2.26)
>4000 3 6.4 682 028d 8.7 0.74 (0.22-2.50)
Gestation liveborn (weeks)c 8.3
<37 4 85.4 19 117 7.1 0.88 (0.32-2.46)
37-40 4le 6.2 172 583 64.5 1.00
>40 3 75 813 28.3 0.17 (0.05-0.54)
aData for each variable are for as many years during 1973-92 as national statistics are available: for stillbirths and
livebirths, 1973-92 (n = 13 054 763) (OPCS, 1977-94); for twin pregnancies 1974-80, 1982-92 (n = 11 744 318)
(OPCS, 1977-94); for birthweight, 1978-90 (n = 7 865 446) (OPCS, 1980-6; OPCS, 1988-93); for gestation 1980,
1982-85 (A Macfarlane: unpublished OPCS data from the Hospital In-patient Enquiry). bNationaldata not available
by sex of the child. cBirthweight not known for two children ofHodgkin's disease patients, gestation not known for
one. dData divided between 3500- 3999 and >4000g categories only available for 1978-85; the proportions for this
period were thereforeapplied to the total 3500+ for 1978 -90 to deriveestimateddata forthewholeperiod. eIncluding
five children described simply as of 'term' gestation.
Table m Results of previous studies on cancer, congenital malformations, birthweight, stillbirths and twinning in offspring of patients
receiving radiotherapy or chemotherapy for cancer
Outcome in offspring Results References
Cancer No raised risk Draper (1989), Janov et al. (1992), Aisner et al.
(1993)
Congenital malformations No raised risk in most studies, Senturia et al. (1985), Mulvihill et al. (1987a), Li et
al. (1987), Hawkins, 1991; Green et al. (1991),
Janov et al. (1992), Aisner et al. (1993), Dodds et
al. (1993),
but with exceptions Green et al. (1991), Holmes and Holmes, 1978.
Low birthweight No raised risk in most studies of offspring after Blatt et al. (1980), Horning et al. (1981), Janov et
adult treatment, with one exception. al. (1992), Aisner et al. (1993), McKeen et al.
Raised risk in offspring of patients treated for child- (1979).
hood cancer, believed due to radiation damage
to abdominopelvic structures, not genetic damage Li et al. (1987), Hawkins and Smith, 1989
Stillbirths No raised risk in most studies, Holmes and Holmes, 1978; Blatt et al. (1980),
Horning et al. (1981), Andrieu and Ochoa-Molina,
1983; Lacher and Toner, 1986; Janov et al. (1992),
Aisner et al. (1993).
but not all McKeen et al. (1979), Green and Hall, 1988.
Sex ratio Total of 51 male, 53 female children after treatment Le Floch et al. (1976), Blatt et al. (1980), Andrieu
in all-age or adult series of women treated and Ochoa-Molina, 1983; Whitehead et al. (1983),
for Hodgkin's disease Specht et al. (1984), Lacher and Toner, 1986;
Fourteen male, 12 female children fathered by Aisner et al. (1993).
men with Hodgkin's disease Aisner et al. (1993)
Twinning Four twin pregnancies in 188 to mothers after Baker et al. (1972), Holmes and Holmes, 1978;
Hodgkin's disease in all-age or adult series- Blatt et al. (1980), Horning et al. (1981), Schilsky
over twice the rate in the corresponding et al. (1981), Whitehead et al. (1983), Specht et al.
general populations (Little and Thompson, 1988) (1984), Gabriel et al. (1986), Lacher and Toner,
One twin pregnancy out of 62 to fathers 1986; Kreuser et al. (1987), Aisner et al. (1993),.
after Hodgkin's disease Holmes and Holmes, 1978; Kinsella et al. (1989),
One twin pregnancy to affected parent of Aisner et al. (1993).
unknown sex out of 25 pregnancies Janov et al. (1992).
Risk of twinning not raised after treatment of Li et al. (1979, 1987), Green and Hall (1988), Sy
parent in childhood for Hodgkin's disease or Ortin et al. (1990)
other cancer9 A)~~~~~~~ Swedo eta
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one instance in which as well as natural intercourse, stored
sperm may also have been used. Sixteen of the children had
been born less than 5 years after first treatment, 20 at 5-9
years after, and 13 at 10 or more years after first treatment.
In addition, the female patients had a total of one
miscarriage before first treatment and six after first
treatment, and two terminations before and four after first
treatment. The partners of the male patients had one
miscarriage before and two after first treatment, three
terminations after first treatment, and one stillbirth during
first treatment, all involving a patient as father. The only
abnormality of pregnancy reported by women treated for
Hodgkin's disease was hypothyroidism diagnosed and treated
during a pregnancy 3I/2 years after mantle radiotherapy.
In respect of stillbirths, sex ratio, birthweight and
gestation, the offspring were similar to births nationally
(Table HI). The results were similar for offspring of each sex
of patient separately (not shown in table). Two pairs of twins
were born to female patients, a significant excess over
expectations (relative risk=8.52; P=0.025). In both in-
stances the mother had been treated with chemotherapy;
one with MOPP (mustine, vincristine, prednisone, procarba-
zine) and the other with LOPP (chlorambuciL vincristine,
procarbazine and prednisone) alternating with EVAP
(etoposide, vinblastine, doxorubicin, prednisone). Both twin
pairs were like-sex; one pair were considered visually
'identical' by the parents, and the other pair visually 'not
identical'.
At interview, congenital abnormalities were reported in
four of the offspring born after treatment (Down's syndrome
in a child born to a male patient; a small cyst on the head, a
Mongolian blue spot, and a minor birthmark, in children of
female patients). 'Macroglossia with a hearing problem' was
reported in a child born before treatment to a female patient.
Although formal 'expected' rates cannot be calculated
precisely, because of differences in methods of data
collection, definitions and completeness between our data
and malformation registers., the rates of malformation in our
patients do not appear to be above those in registry data
(Knox and Lancashire, 1991). No cancers had occurred in the
children, among whom at the time of interview 24 were aged
0-4 years, 19 aged 5-9 years and six older than 9 years.
We obtained blood samples from 45 children (one male
and one female conceived before treatment; 21 males and 22
females conceived after treatment) of 25 patients. These
included four children to men and ten to women after
treatment with chemotherapy, 11 to men and ten to women
after treatment with radiotherapy (mantle or localised upper
body radiotherapy), and seven to men and one to a woman
after treatment with combined modalities (in five instances
involving radiotherapy directly to the gonads, in the other
three involving mantle radiotherapy). All ofthe samples were
normal 46,XY or 46,XX except one child born after
treatment who had Down's syndrome, with the chromosome
constitution 47,XY,+21. For one further patient we were
informed that an intrauterine death had occurred after
treatment and the fetus had triploidy. Histopathology
indicated a partial hydatidiform mole and we were able to
determine the chromosome constitution as 69,XXY. Another
patient had a termination of a pregnancy occurring after
treatment, for which fetal blood examination showed a 45,X
karyotype. The parents of the Down's syndrome patient and
the triploid and Turner's fetuses all had normal chromo-
somes. For the first two of these abnormalities, molecular
genetic analyses of DNA showed that the origin of the
abnormality was from the patient who had not had
Hodgkin's disease; in the third instance (45,X), DNA to
determine parental origin could not be extracted from the
pathological material available.
The finding of no chromosome abnormality attributable to
the treated parent among 43 children conceived after
treatment gives 95% confidence limits for the percentage of
such abnormalities of 0-8.2%. For the 21 children conceived
after chemotherapy, the 95% confidence limits are 0- 16.1%.
Although we were able to examine the BNLI records for all
subjects and the case notes for almost all, there were
appreciable numbers for whom it proved impossible to
make personal recontact up to 22 years after first
treatment. For females, we probably ascertained from the
case notes virtually all children born after treatment, as the
questionnaires revealed none who were not recorded in the
case notes. For males, however, a third of the patients for
whom children born after treatment were identified did not
have them recorded in the case notes, suggesting that we may
have missed some among men who did not reply to the
questionnaire. The diminishing fertility of women with older
age at treatment in our data accords with other studies
(Horning et al., 1981).
Since radiotherapy and several cytotoxic drugs used for
cancer chemotherapy are known to be highly mutagenic, it
seems reasonable that they might cause germ cell mutations
in man (Draper, 1989). In laboratory animals, radiation and
various chemicals applied before mating to males or females
have been shown to produce cancers and congenital
malformations in the offspring (Nomura, 1982, 1988; Trasler
et al., 1985). No cancers or apparent excess of congenital
malformations occurred in the offspring in our study.
Although we cannot be sure whether malformations or
cancers occurred in the offspring of subjects who were not
interviewed, we know of none, and they did not occur in the
nine uninterviewed patients with children after treatment who
returned the postal questionnaire. Previous studies overall
also do not suggest raised risk of abnormal pregnancy
outcomes or childhood cancer from preconceptional exposure
to cancer radiotherapy or chemotherapy (Table III), but
based on modest numbers, and with power, especially for
childhood cancers (Draper, 1989), not great. There is also no
consistent evidence of transgenerational carcinogenesis in
other groups exposed to potential mutagens (Draper, 1989;
Yoshimoto et al., 1990; Doll et al., 1994), and no excess of
congenital malformations (Otake et al., 1990), untoward
pregnancy outcomes, chromosome abnormalities, mutations
affecting protein charge or function, or alteration in sex ratio
(Neel et al., 1990) in children of atomic bomb survivors,
although the exposure differs from prolonged courses of
radiotherapy or chemotherapy.
The sex ratio of offspring might give an indication of
genetic damage since lethal mutations on the X chromosome
would cause a deficit of sons (Rucknagel, 1981), but neither
our data nor the literature (Table HI) suggest this occurs.
The excess of twins in our data has not been remarked
upon before, but is seen also in the aggregated literature for
adult but not childhood cancer patients (Table III). Although
based on small numbers, there are reasons why this is
plausible. Treatment of Hodgkin's disease in adulthood leads
to premature ovarian failure and raised pituitary gonado-
trophin levels, which may precede menopause (Schilsky et al.,
1981). Treatment in childhood, however, although it may
cause ovarian failure soon after treatment (i.e. before adult
ages), appears rarely to lead to premature menopause after a
period of ovarian function when pregnancy could occur (Sy
Ortin et al., 1990). Incidence of dizygotic twinning in the
general population rises with maternal age (except beyond
age 40), which is believed to relate to rising pituitary
gonadotrophin levels (Campbell, 1988). Thus the hormonal
and ovarian effects of treatment of Hodgkin's disease in
adulthood may be equivalent in terms of twinning aetiology
to the hormonal and ovarian state ofwomen reaching natural
menopause at ages considerably older than these patients
(indeed one of the mothers of twins in our study entered
premature menopause after bearing her twins).
Genetic damage by therapy need not lead to any of the
above outcomes, and when they do occur they are frequently
not caused by genetic damage. Direct examination of
chromosome constitutions provides a powerful method to
examine whether or not a certain type of transgenerationalorvdrp in mihs A~ passb
A) Swerow et i
295
genetic effect is occurring, especially sincexamination of
parental chromosomes can determine the parental origin of
an abnormality. We found no chromosome abnormalities
attributable to the treated parent However, chromosome
analysis will not detect subtle changes to the DNA, including
conventional mutations. In the general population almost 1%
of individuals have a chromosome abnormality when similar
levels of banding are used (Jacobs et al., 1992). Our findings
enable us to rule out at the 95% level ofconfidence that more
than 8% of offspring in the study group overall would have
had abnormalities, and larger percentages for subgroups of
the data. About half of the patients had received
chemotherapy and had therefore had a large mutagenic
dose to the gonads. The other halfhad radiotherapy alone, to
the upper body, so that their gonadal dose will have been far
lower, from scattered radiation. Larger studies with
chromosome data would be desirable.
In conclusion, our results and the literature so far are
reassuring with respect to pregnancies conceived after
chemotherapy and radiotherapy, although the numbers
studied are not large enough to exclude quite substantial
and important risks or to give satisfactory analyses for
specific chemotherapeutic regimens. Further surveillance is
needed, to increase the number of children on which risk
assessments are based, to give sufficient cases for analyses in
relation to specific therapeutic agents, and to re-test whether
treatment gives rise to twinning.
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